此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

胆碱能增强θ波

2026年9月23日 更新者:Bradley Lega、University of Texas Southwestern Medical Center

毒蕈碱激动剂对记忆处理振荡活动的调节

The goal of this study is to learn about the effects of Cobenfy KarXT (xanomeline and trospium chloride) on episodic memory processing, including specific effects on areas of the brain involved in memory and changes it may have on brain activity. The investigators will do this by testing epileptic patients who are already undergoing intracranial surgery for seizure monitoring, and measuring the activity from the brain areas being assessed.

The main questions it aims to answer are 1) whether Cobenfy KarXT changes memory activity based on its agonist effect on muscarinic receptors and acetylcholine, and 2) what the nature of these brain activity changes are. This work builds on previous experiments evaluating cholinergic antagonists.

Participants will complete two treatment arms. One of these will be with the drug, and the other will be control session. Participants will not be blinded to the study condition. Patients will complete a verbal serial recall and/or associative recognition task each of the two days. An anesthesiologist or patient nurse will administer either the drug or the placebo at a critical point which addresses both of the research questions.

Researchers will compare the brain activity between the two treatment arms to determine what brain activity changes, and whether there is an additional behavioral effect on memory.

研究概览

详细说明

Patient Identification: The study team plans to recruit adult patients who are undergoing invasive electroencephalographic (EEG) monitoring as part of standard clinical procedure for the treatment of pharmacologically resistant epilepsy at UT Southwestern. Patients are identified from the pool of patients presented at the epilepsy management conference and approached when they present to the clinic for evaluation for seizure surgery. Patients are screened by a coordinator as well as anesthesiologist on the study team for contraindications which make them ineligible for receiving the drug.

Study procedures: Participation takes place only during the time that the electrodes are surgically in place. Active participation will end when the electrodes are removed. Tasks described below will be administered by key personnel on the study. The data will be de-identified and converted to signal data for processing and analysis. Study personnel, excluding the PI (aka 'experimenters') will perform analysis.

Once patients are in the epilepsy monitoring unit (EMU), subjects will be randomized to receive either a dose of 50 mg/20 mg orally BID of xanomeline and trospium chloride (COBENFY) for their initial session, or complete a control session. Approximately 2 hours after administration in the drug condition, the participant will complete an episodic memory task session. At least 24 hours following the first session (at least four half-lives after the first session), the participant will either receive the agent, or complete the control, depending on the first session. For example, if the patient received COBENFY the first day, they would complete the control the second day, and vice versa. Again, in the drug condition, the episodic memory task would occur 2 hours after administration.

Day 1: Randomized to receive either COBENFY or complete a control session (no drug); Complete episodic memory task session Day 2: Alternative session (control or CONBENFY) from day 1; Completes episodic memory task session

Neither participants nor researchers are blind to administration of Cobenfy KarXT, but this should not greatly impact the science of the study. Although there may be some performance effects, participants are being told that the drug may effect a particular brain activity, which may be difficult to model. The randomization will be generated by the pharmacy using a psuedorandomizer.

The participant's attending nurse will administer Cobenfy KarXT for the drug sessions 2 hours prior to the test.

Physiologic Monitoring: Patients in the epilepsy monitoring undergo EKG and pulse oxygen monitoring in addition to seizure monitoring electrodes at all times as part of routine care and this will not be interrupted during the study period. There is a certified epilepsy monitoring team available should the cholinergic effects enhance seizures. A board-certified anesthesiologist with specialist practice in neuroanesthesia will be immediately available within the hospital to respond with any other concerns. In our previous experiments using cholinergic modulation (antagonism), there have not been any adverse events. Specifically, there has not been an impact on seizure activity. While we do not anticipate an effect of Cobenfy KarXT on seizure activity, we note that all patients are located in the EMU environment with 2:1 nursing ratios and immediately available protocols for interventions if seizures occur.

Overview of Memory Testing: Episodic memory tasks in our lab typically last 30-75 minutes provided patient does not request a break during the task. There is no physical risk to participants from cognitive tasks. Participants may stop and resume each task whenever they need a break. Participants for this protocol would need to wait at least 24 hours/six half-lives following completion of one of the testing sessions prior to completing the second, regardless of whether administration of Cobenfy KarXT occurred. The cognitive tasks will cause patients to incur no additional medical or surgical risk; rather patients often report the game-like testing protocols provide relief from the boredom of awaiting seizures. Within each session, patients may request breaks to avoid fatigue. Testing may also be paused or interrupted for any health-care-related needs. The research team will attend to the comfort of all participants, who may discontinue the testing at any time, without repercussions.

Episodic Memory Tasks: Patients will participate in verbal memory tasks, such as lists of specific words to be recalled freely or in a serial order. such lists are comprised of words or nameable pictures. A computer controls stimulus presentation and records participants' response of words or word order. Each list is followed by a brief distractor task consisting of a simple addition or subtraction problem prior to recall. This end-of-list distracter task serves to reduce the large advantage accorded to end-of-list items during recall, or recency effect. There are approximately 10-12 words or items in one list. Participants are then given the opportunity to place these words in the order they recall them. Their responses are digitally recorded by the computer and anonymously stored for later analysis. This paradigm cannot specifically address questions regarding differences on encoding versus retrieval, so patients may be also be given other types of verbal memory tasks, such as recognition paradigms of associative recognition, or other verbal tasks that will be able to parse out such aspects of episodic memory.

Collection of iEEG data: Patients included in the study undergo the acquisition of EEG data for clinical purposes by clinicians, using a computerized EEG collection system. In this study, we will copy these data, strip them of any confidential information, and analyze the raw traces of EEG. Synchronization of the experimental computer with the iEEG signals is accomplished by sending an optically isolated pulse to an input on the EEG recording system. This train of pulses enables the iEEG record to synchronize itself with the testing computer, in standard fashion for this work.

研究类型

介入性

注册 (估计的)

50

阶段

  • 第一阶段早期

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Texas
      • Dallas、Texas、美国、75390

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 75年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Age 18 - 75 years, all races/ethnicities, and both genders are eligible.
  2. Candidates for pre-operative evaluation using stereo intracranial electrodes and admission to the Epilepsy Monitoring Unit (EMU) as determined independently by the patient's treating physician as part of the patient's routine medical care.
  3. Able to read, understand, and provide written, dated informed consent prior to screening.
  4. In good general health, aside from a history of epilepsy, as ascertained by medical history, physical examination (PE), clinical laboratory evaluations, and ECG.

Exclusion Criteria:

  1. Has a clinically significant abnormality on the screening physical examination that might affect safety, study participation, or confound interpretation of study results according to the study physician.
  2. Female that is pregnant, breastfeeding, or has a positive pregnancy test at screening or baseline. We note that pregnant patients are excluded from undergoing iEEG.
  3. Hepatic impairment (moderate or severe).
  4. Renal impairment (moderate or severe).
  5. Clinically significant bladder outlet obstruction or incomplete bladder emptying, such as patients with prostatic hyperplasia (BPH), diabetic cystopathy, pre-existing urinary retention.
  6. History of hypersensitivity to COBENFY or trospium chloride (angioedema risks).
  7. Untreated narrow-angle glaucoma.
  8. Biliary Disease (symptomatic gallstones, gallbladder disorders, pancreatitis).
  9. Strong Inhibitors of CYP2D6 such as fluoxetine, paroxetine, bupropion, terbinafine.
  10. Sensitive Substrates of CYP3A4 such as buspirone, eletriptan.
  11. Narrow Therapeutic Index Substrates of P-glycoprotein such as digoxin, colchicine, apixaban.
  12. Drugs Eliminated by Active Tubular Secretion.
  13. Antimuscarinic Drugs such as diphenhydramine, benztropine, oxybutynin.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:基础科学
  • 分配:随机化
  • 介入模型:交叉作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:COBENFY KarXT (50/20 mg)

Subjects will receive a dose of COBENFY KarXT (50/20 mg). Approximately 2 hours minutes after administration, the participant will then complete an episodic memory task session. If the patient completed the control session already, this session will take place minimum of 24 hours following the initial session, or at least four half-lives after the first session.

Patient receives a dose of COBENFY KarXT (50/20 mg) 2 hours prior to episodic memory task.

其他:Control

Subjects will complete a control session comparator. The participant will then complete an episodic memory task session without receiving the pharmacological intervention. If the patient completed the COBENFY KarXT session already, this session will take place minimum of 24 hours following the initial session, or at least four half-lives after the first session.

Patient receives a dose of placebo 2 hours prior to episodic memory task.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Memory-related changes in brain electrical activity in participants from baseline at Day 1 post-intervention (approx. within 1-3 hrs)
大体时间:Baseline, at Day 1 post-intervention (approx. within 1-3 hrs)

Memory-related changes in brain electrical activity in participants from baseline at post-intervention (approx. within 1-3 hrs) is measured by comparing the Free recall memory tasks with the electrical readings collected across all bandwidths, but focusing on primarily theta power and oscillatory changes. Other changes, such as phase amplitude coupling, may also be considered.

Baseline, at Day 1 post-intervention (approx. within 1-3 hrs)
Memory-related changes in brain electrical activity in participants from baseline at Day 2 post-intervention (approx. within 1-3 hrs)
大体时间:Baseline, at Day 2 post-intervention (approx. within 1-3 hrs)

Memory-related changes in brain electrical activity in participants from baseline at post-intervention (approx. within 1-3 hrs) is measured by comparing the Free recall memory tasks with the electrical readings collected across all bandwidths, but focusing on primarily theta power and oscillatory changes. Other changes, such as phase amplitude coupling, may also be considered.

Baseline, at Day 2 post-intervention (approx. within 1-3 hrs)
Memory-related changes in brain electrical activity in participants from baseline at Day 1 post-intervention (approx. within 1-3 hrs)
大体时间:Baseline, at Day 1 post-intervention (approx. within 1-3 hrs)

Memory-related changes in brain electrical activity in participants from baseline at post-intervention (approx. within 1-3 hrs) is measured by comparing the serial recall memory tasks with the electrical readings collected across all bandwidths, but focusing on primarily thetapower and oscillatory changes. Other changes, such as phase amplitude coupling, may also be considered.

Baseline, at Day 1 post-intervention (approx. within 1-3 hrs)
Memory-related changes in brain electrical activity in participants from baseline at Day 2 post-intervention (approx. within 1-3 hrs)
大体时间:Baseline, at Day 2 post-intervention (approx. within 1-3 hrs)

Memory-related changes in brain electrical activity in participants from baseline at post-intervention (approx. within 1-3 hrs) is measured by comparing the serial recall memory tasks with the electrical readings collected across all bandwidths, but focusing on primarily theta power and oscillatory changes. Other changes, such as phase amplitude coupling, may also be considered.

Baseline, at Day 2 post-intervention (approx. within 1-3 hrs)
Memory-related changes in brain electrical activity in participants from baseline at Day 1 post-intervention (approx. within 1-3 hrs)
大体时间:Baseline, at Day 1 post-intervention (approx. within 1-3 hrs)

Memory-related changes in brain electrical activity in participants from baseline at post-intervention (approx. within 1-3 hrs) is measured by comparing the associative recognition memory tasks with the electrical readings collected across all bandwidths, but focusing on primarily theta power and oscillatory changes. Other changes, such as phase amplitude coupling, may also be considered.

Baseline, at Day 1 post-intervention (approx. within 1-3 hrs)
Memory-related changes in brain electrical activity in participants from baseline at Day 2 post-intervention (approx. within 1-3 hrs)
大体时间:Baseline, at Day 2 post-intervention (approx. within 1-3 hrs)

Memory-related changes in brain electrical activity in participants from baseline at post-intervention (approx. within 1-3 hrs) is measured by comparing the associative recognition memory tasks with the electrical readings collected across all bandwidths, but focusing on primarily theta power and oscillatory changes. Other changes, such as phase amplitude coupling, may also be considered.

Baseline, at Day 2 post-intervention (approx. within 1-3 hrs)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Bradley C Lega, MD、University of Texas Southwestern Medical Center

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年12月1日

初级完成 (估计的)

2031年12月1日

研究完成 (估计的)

2031年12月1日

研究注册日期

首次提交

2025年11月12日

首先提交符合 QC 标准的

2025年11月12日

首次发布 (实际的)

2025年11月14日

研究记录更新

最后更新发布 (实际的)

2026年9月29日

上次提交的符合 QC 标准的更新

2026年9月23日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅